EGFR and colorectal carcinoma: Indeed, in the setting of mCR, in addition to conventional chemotherapy drugs, several agents targeting the molecular drivers of CRC pathogenesis, including signaling pathways mediated by the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF), have been tested in such patients, increasing survival rates.